 |
|
|
|
|
|
|
|
 |
Results for 'Competitor Analysis: Psoriasis' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Cannabinoid CB1 receptor antagonists
Competitor Analysis
|
November 2008 |
£85 |
70 % |
Erythropoietin (EPO)
Competitor Analysis
|
July 2008 |
£340 |
70 % |
Diabetes Drug Pipeline
Competitor Analysis
|
November 2008 |
£415 |
70 % |
Insulin
Competitor Analysis
|
October 2008 |
£275 |
70 % |
Interferon
Competitor Analysis
|
November 2008 |
£285 |
70 % |
Peroxisome Proliferator-Activated Receptor (PPAR) Agonists
Competitor Analysis
|
November 2008 |
£210 |
70 % |
Follicle Stimulating Hormone (FSH)
Competitor Analysis
|
November 2008 |
£125 |
70 % |
Novozymes A -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Nutrition 21 Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Novogen Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Novavax Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Nuvelo Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Cephalon Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Oragenics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
CV Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Novartis AG -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Oncothyreon, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
OncoVista, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
OXiGENE INC -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
NexMed Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Neurochem Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
NeoPharm Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
NatureWell Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
CombinatoRx Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Neurogenesis Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
NeurogesX, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Novacea Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Nitromed Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Orthovita Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Neurologix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Chattem Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Bionovo Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Proteo Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Bayer Ag -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Protalex Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Benitec Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
BioTime Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Psivida Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
QLT Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
AutoImmune Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Avigen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Replidyne Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Renovis Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Biocon Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Phosphagenics Ltd. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
NanoViricides, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Peplin Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Biosyntech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Gentium S.p.A -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Pfizer Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Pharmacopeia, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Biodel Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Pharmaxis Ltd. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Pharmasset, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Pharmacyclics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Osteologix, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Curis Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Eqitx Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Epigenomics AG -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Eurand N.V. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Exelixis Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Immunomedics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Inhibitex Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
EntreMed Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
IsoRay Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Inyx Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
InterMune Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Endovasc Inc (NV) -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
ImmunoGen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Favrille Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
GenVec Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
H.Lundbeck AS -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Genentech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
GeoPharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Hemobiotech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Hologic Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Imagenetix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
ICAgen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
GTX INC -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Hospira Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
3SBio Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Eisai Co Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
MethylGene Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
MicroIslet, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
CytoDyn Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Cytogenix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Cytokinetics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Micromet Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Migenix Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Mylan, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Crucell N V -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Modigene, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Athersys, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Medivation Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Medicure Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Lescarden Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Lannett Co Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Labopharm Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
KV Pharmaceutical Co. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Lpath Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Depomed Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
MediciNova Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Medarex Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Maxygen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Mannatech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Compugen Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
POZEN Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Alpharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Actelion Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
StemCells Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
SuperGen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
AlphaRx Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
VIA Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
VIVUS Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Vasogen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Vical Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Sinobiomed Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Antigenics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Sepracor Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Viropharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Anesiva, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Amgen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Viragen Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
SyntheMed Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Acusphere Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Alchemia Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Tercica Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Telik Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Advaxis Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Akorn Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Theravance Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Affymax Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Alcon Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
AtheroGenics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Alkermes Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Allergan Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
TapImmune, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Targacept Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Trimeris Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
ULURU Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
ArQule Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Amdl Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Zila Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
AP Pharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Wyeth -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Santarus Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
YM BioSciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Xenoport Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
ZymoGenetics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
XELR8, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
XOMA Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Astralis Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
50 % |
Acura Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GPC Biotech AG -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GW Pharmaceuticals PLC -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cytos Biotechnology AG -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Forticell Bioscience, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GammaCan International Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
DENTSPLY International Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AMAG Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
DUSA Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GTC Biotherapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Adams Respiratory Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
DRAXIS Health Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dendreon Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
DOR BioPharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
DURECT Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
GelStat Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Genitope Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Generex Biotechnology Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Genelabs Technologies Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Aeolus Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cyclacel Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Genta Incorporated -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cyanotech Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
ADVENTRX Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Genaera Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Advanced Life Sciences Holdings Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AEterna Zentaris Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Acorda Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Adherex Technologies Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Adolor Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
CytRx Corporation -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cyplasin Biomedical Ltd. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Cypress Bioscience Incorporated -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Gedeon Richter Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Diamyd Medical AB -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Encysive Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Endo Pharmaceuticals Holdings Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Aastrom Biosciences Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Enhance Biotech Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Emisphere Technologies Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Emergent BioSolutions Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Eli Lilly & Co -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Elite Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Abbott Laboratories -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
APP Pharmaceuticals, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
ARYx Therapeutics, Inc. -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AVANT Immunotherapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AVI BioPharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Eugene Science Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
EpiCept Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Enzon Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Enzo Biochem Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AXM Pharma Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AVANIR Pharmaceuticals -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Acadia Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Flamel Technologies SA ADS -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Forest Laboratories Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dr Reddys Laboratories Ltd -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Access Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dragon Pharmaceutical Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Achillion Pharmaceuticals Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dov Pharmaceutical Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
AVAX TECHNOLOGIES INCORPORATED -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Discovery Laboratories Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dnaprint Genomics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Duska Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
Dyax Corp -Therapeutic Competitors
|
February 2008 |
£175 |
49.5 % |
CuraGen Corp -Therapeutic Competitors
|
February 2008 |
£175 |
